Aventis will continue to promote unique qualities of Allegra (fexofenadine), the company said, stressing studies showing superior nonsedating benefits. In January 2002, Schering-Plough launched Clarinex (desloratadine), its successor to Claritin. A later look at the prescription zyrtec 10mg bottle showed that it contained Zyprexa (olanzapine), an antipsychotic agent. As always, whenever you can’t clearly read the name of an ordered medication, check with the person who wrote the order. (Nasdaq: TEVA) zyrtec 10mg announced today that the U. The FDA approved five formulations of Claritin for OTC sale Nov. In Medication Errors, we try to keep you updated on drug name similarities and potential mix-ups. Zyrtec 10mg such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Teva’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Final approval is anticipated upon expiration of patent protection on December 25, 2007. The brand product has annual sales of approximately $1. 2 billion. Teva Pharmaceutical Zyrtec 10mg industries Ltd. , headquartered in Israel, is among the top 25 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Besides having names that begin with Zy, both drugs are available in white, coated, 5-mg and 10-mg tablets and generally are taken by mouth once a day Patients with unusual adverse reactions to drugs should be instructed to show the drug to Zyrtec 10mg the pharmacist for verification. Plans usually do not cover non-prescription drugs and may push for use of OTC Claritin. It is available in 5mg and 10mg tablets, 5mg and 10mg chewable tablets, and 1mg/mL syrup. Close to 90% of Teva’s sales are in zyrtec 10mg north America and Europe. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Securities and Exchange Commission. First, UCB Japan has agreed with its sales partner Sumitomo Pharmaceuticals to terminate the distribution agreement for Zyrtec, effective June 30.